CMV (Cytomegalovirus) - specific dendritic cell vaccine trial summary

https://sci-hub.tw/https://clincancerres.aacrjournals.org/content/early/2020/07/25/1078-0432.CCR-20-1082.long

Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma

"We have now observed that nearly one-third of the GBM study patient population receiving CMV-specific DC vaccines results in exceptional long-term survivors."

New cytomegalovirus-directed vaccine trial for recurrent GBM

This phase 1 trial opened this month in New York, and will be opening in Virginia as well.

The vaccine is called VBI-1901 and consists of two CMV antigens (gB and pp65), delivered via enveloped virus-like particles (eVLP), plus GM-CSF as an adjuvant.

View trial outline here.

Navigating the Brain Tumor Maze with Professor Rajiv Khanna

This will be particularly interesting for patients in Australia and much of the discussion is about CMV-directed T-cell therapy being developed there in Brisbane.  The discussion turns to GBM at minute 25:25 of the podcast.  Click here for the link.

Not sure this is news or not.

https://scienceblog.com/492536/study-finds-no-evidence-common-herpes-type-virus-aggressive-brain-cancer-tissue/

I was curious to there is a low grade trial. 

Continue Valcyte or not...

Hi All,
My brother has been taking Valcyte for 22 months. Today after a great MRI result his oncologist has suggested stopping Valcyte.
What are your thoughts?
Best wishes, Lisa

New trial at MD Anderson (Houston) for newly diagnosed or first recurrent GBM

A Phase I/II Clinical Trial of Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients (click here to view detailed trial description)

This is a phase 2, non-randomized, open-label trial.

There are 3 arms: first, a dose expansion study to find the maximum tolerated dose of the CMV-specific T-cells in recurrent GBM at first relapse, along with dose-dense temozolomide.

After finding the maximum tolerated dose, the second arm of recurrent GBM patients undergoes temozolomide treatment for 21 days followed by the first administration of CMV-specific T-cells, followed by surgery for the recurrent tumor on day 30.  After surgery patients undergo another 3 cycles of dose-dense temzolomide followed by T-cell infusions.  Temozolomide is continued for a maximum of 12 cycles or until disease progression.

The third arm consists of newly diagnosed GBM patients treated with dose-dense temozolomide and CMV-specific T-cells, after conventional radiochemotherapy.

All patients undergo a leukapheresis procedure to obtain T-cells, which are reinjected after conditioning.

Artusunate and CMV

Stephen

Do you have any information on the results from this study?  https://clinicaltrials.gov/ct2/show/NCT00284687.  The study looked at the affect artusunate had on CMV.  The CUSP 9 paper mentioned Artusunate was effective against CMV.  If this is indeed correct, then it might be a far less expensive approach to CMV than valcyte.

Mike

Seattle Science Foundation Lecture Link Available

Hi -

Finally got the link to the lecture from the event at the Seattle Science Foundation: https://www.youtube.com/watch?v=tEWU6TDoR9Y&list=PLyptnEaqO5i5pTEYxgouH61Twgp3I5vMt&index=1

Dr. Soderberg's presentation was not published per her request.  Apparently it's unpublished data.  To summarize what I got from it, 100% of GBM tumors test positive for CMV.  In Sweden 150 +/- GBM patients were given valcyte.  30 were recurrent, the rest newly diagnosed.  All saw benefit.  It's cheapest (for the US anyway) at Mark's Marine Pharmacy in CA (generic is $800 per month).


Thanks.
Annie